ID28006A - Komposisi analog nukleotida - Google Patents

Komposisi analog nukleotida

Info

Publication number
ID28006A
ID28006A IDW20000153A ID20000153A ID28006A ID 28006 A ID28006 A ID 28006A ID W20000153 A IDW20000153 A ID W20000153A ID 20000153 A ID20000153 A ID 20000153A ID 28006 A ID28006 A ID 28006A
Authority
ID
Indonesia
Prior art keywords
nucleotide analog
analog composition
composition
nucleotide
analog
Prior art date
Application number
IDW20000153A
Other languages
English (en)
Indonesian (id)
Inventor
Murty N Arimilli
Thomas T K Lee
Lawrrence V Manes
John D Munger Jr
Ernest J Prisbe
Lisa M Schultze
Daphne E Kelly
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26732226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID28006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ID28006A publication Critical patent/ID28006A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transplanting Machines (AREA)
IDW20000153A 1997-07-25 1998-07-23 Komposisi analog nukleotida ID28006A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90074597A 1997-07-25 1997-07-25
US5377197P 1997-07-25 1997-07-25

Publications (1)

Publication Number Publication Date
ID28006A true ID28006A (id) 2001-05-03

Family

ID=26732226

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000153A ID28006A (id) 1997-07-25 1998-07-23 Komposisi analog nukleotida

Country Status (24)

Country Link
EP (1) EP0996430B1 (no)
JP (4) JP3573713B2 (no)
KR (3) KR100700087B1 (no)
CN (2) CN1216062C (no)
AR (1) AR016548A1 (no)
AT (3) ATE277936T1 (no)
AU (1) AU747163B2 (no)
BR (1) BR9811552A (no)
CA (3) CA2298057C (no)
CO (1) CO4980869A1 (no)
DE (3) DE69826735T2 (no)
DK (1) DK0996430T3 (no)
ES (3) ES2229030T3 (no)
HK (5) HK1046357B (no)
ID (1) ID28006A (no)
IL (1) IL133461A (no)
IN (1) IN190037B (no)
MY (1) MY129451A (no)
NZ (1) NZ501659A (no)
PT (3) PT1256584E (no)
SI (2) SI1256584T1 (no)
TR (3) TR200200117T2 (no)
TW (1) TW584635B (no)
WO (1) WO1999004774A2 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1256584E (pt) * 1997-07-25 2004-12-31 Gilead Sciences Inc Processo para a preparacao de adefovir-dipivoxil
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US6635278B1 (en) * 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
AU2001282941C1 (en) 2000-07-21 2016-12-22 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
JP4476811B2 (ja) 2002-05-13 2010-06-09 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ
CA2485597C (en) 2002-05-13 2013-07-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
CN100383149C (zh) * 2002-11-12 2008-04-23 天津帝士力投资控股集团有限公司 一种新的晶状埃地双酯及其组合物
GB2413556B (en) * 2002-11-12 2007-03-14 Tianjin Kinsly Pharmaceutical A new crystal form of adefovir dipivoxil and its composition
CN1303089C (zh) * 2002-11-19 2007-03-07 天津药物研究院 阿德福韦酯结晶形态及其制备方法
CN100415756C (zh) * 2003-10-14 2008-09-03 沈阳药科大学 草酸阿地福韦酯及其晶型和制备方法及用途
CN100358907C (zh) * 2004-03-31 2008-01-02 河北医科大学生物医学工程中心 一种非晶状阿德福韦酯的制备方法
CN100374118C (zh) * 2004-05-20 2008-03-12 江苏吴中中药研发有限公司 含有阿德福韦酯的滴丸剂及其制备方法
CN1964967B (zh) 2004-06-08 2014-04-16 症变治疗公司 路易斯酸介导的环状酯的合成
US20100216822A1 (en) * 2005-06-13 2010-08-26 Brightgene Bio-Medical Technology Co., Ltd. Nucleotide Analogue Prodrug and the Preparation Thereof
CN100395248C (zh) * 2006-05-26 2008-06-18 华东理工大学 一种9-(二乙氧基磷酰基甲氧基乙基)-腺嘌啉的制备方法
ITMI20071594A1 (it) * 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
CN101343290B (zh) * 2008-05-24 2011-02-02 广东肇庆星湖生物科技股份有限公司 一种阿德福韦酯无水结晶物的制备方法、所得的阿德福韦酯无水结晶物及其应用
WO2010005195A2 (ko) * 2008-07-07 2010-01-14 (주)아모레퍼시픽 아데포버 디피복실의 결정형 ｌ의 제조방법
KR20100031045A (ko) 2008-09-11 2010-03-19 씨제이제일제당 (주) 아데포비어 디피복실의 정제방법
CN102149715A (zh) * 2008-09-17 2011-08-10 Cj第一制糖株式会社 肝适能的稳定化固态分散物及其制备方法
KR20100032803A (ko) 2008-09-18 2010-03-26 씨제이제일제당 (주) 아데포비어디피복실의 개선된 제조방법
KR20100061401A (ko) * 2008-11-28 2010-06-07 (주)아모레퍼시픽 아데포버 디피복실의 결정형, 그 제조방법 및 그를 포함하는 약제학적 조성물
TR201109333T1 (tr) * 2009-03-26 2012-01-23 Daewoong Pharmaceutical Co. Ltd. Adefovir dipivoksilin yeni kristal formları ve bunların hazırlama işlemleri.
KR20100113302A (ko) * 2009-04-13 2010-10-21 한미홀딩스 주식회사 결정형 아데포비어 디피복실의 제조방법 및 이에 사용되는 아데포비어 디피복실 부탄올레이트
KR101528754B1 (ko) * 2009-04-14 2015-06-17 중앙대학교 산학협력단 신규한 복합결정형의 화합물, 그 제조방법 및 이를 포함하는 약제학적 조성물
KR100971486B1 (ko) * 2009-06-11 2010-07-21 주식회사 셀트리온화학연구소 아데포비어 다이피복실 말론산염 및 이를 포함하는 약제학적 조성물
KR101089620B1 (ko) * 2009-07-20 2011-12-06 경희대학교 산학협력단 무수결정형 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법
WO2011016611A2 (ko) * 2009-08-03 2011-02-10 제일약품주식회사 새로운 결정형을 갖는 아데포비어 디피복실, 이의 제조방법 및 이를 유효성분으로 함유하는 만성 ｂ형 간염의 예방 또는 치료용 조성물
KR101129575B1 (ko) * 2009-09-02 2012-03-28 경희대학교 산학협력단 반수화물 아데포비어 디피복실 및 이온성 액체를 사용한 이의 제조 방법
KR101048024B1 (ko) * 2009-10-09 2011-07-13 주식회사 삼오제약 9-(2-포스포닐메톡시에틸)아데닌, 아데포비아 디피복실 및 무정형 아데포비아 디피복실의 제조방법
EP2343056A1 (en) 2009-12-30 2011-07-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Producing stable adefovir dipivoxil solid dispersions
WO2012032541A1 (en) * 2010-09-06 2012-03-15 Matrix Laboratories Ltd "adefovir dipivoxil pseudopolymorph"
WO2012062835A1 (en) 2010-11-12 2012-05-18 Glaxo Wellcome Manufacturing Pte Ltd Novel pharmaceutical compositions
CN102250146A (zh) * 2011-05-27 2011-11-23 扬州三友合成化工有限公司 抗乙肝药物阿德福韦的一种合成方法
KR101357687B1 (ko) * 2011-11-25 2014-02-05 숭실대학교산학협력단 고분자 첨가제를 이용한 아데포비어 디피복실 복합체의 결정입자 제어방법 및 이의 응용
KR101258678B1 (ko) 2012-02-29 2013-04-26 제일약품주식회사 새로운 결정형을 갖는 아데포비어 디피복실, 이의 제조방법 및 이를 유효성분으로 함유하는 만성 β형 간염의 예방 또는 치료용 조성물
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN102816184B (zh) * 2012-09-07 2015-11-18 山东大学 (2-(2-氧基-4-硫代嘧啶)乙氧基)甲基膦酸酯类衍生物及其制备与应用
CN103709198A (zh) * 2012-09-28 2014-04-09 江苏天士力帝益药业有限公司 一种阿德福韦酯的结晶方法
CN103333208B (zh) * 2013-06-04 2016-05-11 广州晶莱医药科技有限公司 阿德福韦酯马来酸盐及其制备方法和组合物
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
EP3372227A1 (en) 2017-03-06 2018-09-12 MH10 Spolka z ograniczona odpowiedzialnoscia Tablet formulation of adefovir dipivoxil
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
ATE199906T1 (de) * 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
JP4033494B2 (ja) * 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
PT1256584E (pt) * 1997-07-25 2004-12-31 Gilead Sciences Inc Processo para a preparacao de adefovir-dipivoxil

Also Published As

Publication number Publication date
ES2229029T3 (es) 2005-04-16
HK1051693A1 (en) 2003-08-15
AR016548A1 (es) 2001-07-25
DE69809749D1 (de) 2003-01-09
JP2005306879A (ja) 2005-11-04
CN1347695A (zh) 2002-05-08
HK1051694A1 (en) 2003-08-15
HK1091212A1 (en) 2007-01-12
PT996430E (pt) 2003-03-31
DK0996430T3 (da) 2003-03-10
JP2003342283A (ja) 2003-12-03
DE69826734D1 (de) 2004-11-04
CO4980869A1 (es) 2000-11-27
DE69809749T2 (de) 2003-09-11
AU8660998A (en) 1999-02-16
ATE277937T1 (de) 2004-10-15
MY129451A (en) 2007-04-30
TW584635B (en) 2004-04-21
JP3573713B2 (ja) 2004-10-06
IN190037B (no) 2003-05-31
ATE228357T1 (de) 2002-12-15
JP2001512712A (ja) 2001-08-28
EP0996430A2 (en) 2000-05-03
KR20010014284A (ko) 2001-02-26
HK1046357A1 (en) 2003-01-10
CN1216062C (zh) 2005-08-24
TR200200137T2 (tr) 2002-09-23
JP2009263389A (ja) 2009-11-12
IL133461A0 (en) 2001-04-30
HK1091211A1 (en) 2007-01-12
ATE277936T1 (de) 2004-10-15
SI1256585T1 (en) 2005-02-28
EP0996430B1 (en) 2002-11-27
ES2187991T3 (es) 2003-06-16
IL133461A (en) 2005-05-17
CN1251592A (zh) 2000-04-26
CA2596320A1 (en) 1999-02-04
PT1256585E (pt) 2005-01-31
WO1999004774A3 (en) 1999-04-15
CN1274700C (zh) 2006-09-13
NZ501659A (en) 2004-12-24
KR100700089B1 (ko) 2007-03-28
CA2596320C (en) 2008-12-23
JP4452034B2 (ja) 2010-04-21
TR200200117T2 (tr) 2002-06-21
KR100618663B1 (ko) 2006-09-08
AU747163B2 (en) 2002-05-09
KR20060038364A (ko) 2006-05-03
TR200000224T2 (tr) 2000-07-21
CA2596497A1 (en) 1999-02-04
ES2229030T3 (es) 2005-04-16
DE69826734T2 (de) 2005-10-06
DE69826735T2 (de) 2005-10-06
PT1256584E (pt) 2004-12-31
CA2596497C (en) 2008-12-23
CA2298057A1 (en) 1999-02-04
WO1999004774A2 (en) 1999-02-04
SI1256584T1 (en) 2005-02-28
CA2298057C (en) 2008-11-18
BR9811552A (pt) 2000-08-29
KR100700087B1 (ko) 2007-03-28
DE69826735D1 (de) 2004-11-04
KR20060038363A (ko) 2006-05-03
HK1046357B (zh) 2007-08-24

Similar Documents

Publication Publication Date Title
DE69809749D1 (de) Nukleotid-analoge zusammensetzung
ZA986614B (en) Nucleotide analog composition
DE69828579D1 (de) Tintezusammensetzung
DE59811578D1 (de) Katalysatorzusammensetzung
IS5430A (is) Ný samsetning
ID22931A (id) Komposisi-komposisi herbisidal
ID22981A (id) Komposisi pengelantang
DE69812370D1 (de) Landwirtschaftliche zusammensetzung
DK1298194T3 (da) Staniolholdige sammensætninger
ID20233A (id) Komposisi oral
DE69832516D1 (de) Isoflavon-enthaltende zusammensetzungen
ID25508A (id) Komposisi dematologis
DE69707551D1 (de) Tintenzusammensetzungen
DE69817385D1 (de) Hochtemperaturbeständige polyurethanzusammensetzungen
ID17774A (id) Komposisi farmasi antitrombosis
DE69822680D1 (de) Tintenzusammensetzungen
DE69706995D1 (de) Tintenzusammensetzung
ID21009A (id) Komposisi untuk supositori
DE69818886D1 (de) Tintenzusammensetzung
DE69832067D1 (de) Farbzusammensetzung
ID21013A (id) Deret nukleotida antipeka
DK0897667T4 (da) Brödforbedrende sammensætning
ID23250A (id) Komposisi paroksetin
ID25650A (id) Komposisi-komposisi sampo
ID21906A (id) Komposisi adesif